Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

461.71 +10.74 (+2.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
54 55 Next >
2 Growth Stocks That Could Double Your Money, According to Wall Street
Find out why investment bank analysts are pounding the table on these stocks. 
Via The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Now?
Jim Cramer recently hyped up one of the company's promising drugs. 
Via The Motley Fool
If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today
Via Benzinga
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Friday Session
Via Investor Brand Network
2 Top Biotech Stocks to Buy Right Now
Both companies are known innovators. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for October
These stocks have oodles of room left to run. 
Via The Motley Fool
Is VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) suited for quality investing?
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
Got $1,000? 2 No-Brainer Stocks to Buy
You can bet the farm on these companies. 
Via The Motley Fool
$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Vertex to Announce Third Quarter 2023 Financial Results on November 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
Wood has outperformed the market so far this year. 
Via The Motley Fool
Jim Cramer's Take on Vertex: Tackling Opioid Addiction with New Drug in Pipeline
CNBC's Jim Cramer has drawn investors' attention to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotechnology company currently in the late stages of developing a non-opioid drug to treat acute pain.  
Via Benzinga
3 Biotech Stocks Ready to Break Out in 2024
These top three biotech companies are ready to roar into the new year with promising new trials, drugs, and innovative use of AI. 
Via InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
The time is right to invest in these great stocks. 
Via The Motley Fool
Jim Cramer: This Company Is 'Arranging Deck Chairs On The Titanic... Not A Believer'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Topgolf Callaway Brands Corp. (NYSE: MODG) is making money. 
Via Benzinga
HP, Zoom Video And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 50 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Biotech Sector: On The Verge Of Triumph Or Turmoil?
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
Via Talk Markets
Vertex Appoints Michel Lagarde to its Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 No-Brainer Stocks to Buy With $1,000 Right Now
A modest amount of money can go a long way when it's invested in highly profitable industry leaders with sustained competitive advantages. 
Via The Motley Fool
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich. 
Via InvestorPlace
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
3 Magnificent Stocks That Are Screaming Buys in October
These stocks give investors something to yell about -- in a good way. 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
These companies are helping change medicine; they could make boatloads of money along the way. 
Via The Motley Fool
2 Brilliant Growth Stocks to Invest $2,000 in Right Now
These growth companies are capitalizing on underserved target markets. 
Via The Motley Fool
5 Top Stocks for October
Venture into October's investment landscape with our five experts, unveiling opportunities in an uneven market environment. 
Via The Motley Fool
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars. 
Via InvestorPlace
The Best Stocks to Invest $5,000 in Right Now
Now is a great time to buy Amazon, Enterprise Products Partners, and Vertex Pharmaceuticals. 
Via The Motley Fool
Why Editas Medicine Stock Is Soaring Today
Investors are cheering a big analyst upgrade for the gene-editing stock. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.